We anticipate that the adoption at open heart centers will continue to be a significant driver of HeartMate II performance in the U.S. for a few reasons.
First and foremost, clinical outcomes at open heart centers have been strong as evidenced by a presentation at ISHLT this year, which I'll discuss in greater detail later. Second, this group of centers is still early in its DT outreach efforts; so far only 19 open heart centers have received DT certification from the Joint Commission. Last, we anticipate that the vast majority of new VAD program development will come from open heart centers. For all these reasons, we’re excited about the growth prospects from the segments.
That said, I would note that many of these centers are early in their adoption of the therapy and we therefore expect performance to have some variability from quarter-to-quarter.